Oric Pharmaceuticals (NASDAQ:ORIC) CEO Jacob Chacko Sells 33,374 Shares of Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko sold 33,374 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $302,368.44. Following the sale, the chief executive officer directly owned 581,711 shares of the company’s stock, valued at $5,270,301.66. This represents a 5.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jacob Chacko also recently made the following trade(s):

• On Monday, October 6th, Jacob Chacko sold 37,461 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $461,519.52.
• On Wednesday, October 1st, Jacob Chacko sold 53,001 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $12.05, for a total value of $638,662.05.
• On Tuesday, September 30th, Jacob Chacko sold 34,538 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $12.01, for a total transaction of $414,801.38.
• On Monday, September 22nd, Jacob Chacko sold 125,000 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.80, for a total transaction of $1,350,000.00.

Oric Pharmaceuticals Trading Down 9.9%

NASDAQ ORIC traded down $0.90 on Wednesday, hitting $8.22. 1,544,554 shares of the company were exchanged, compared to its average volume of 1,174,600. The company has a market cap of $800.55 million, a PE ratio of -4.75 and a beta of 1.32. The stock has a fifty day moving average of $11.94 and a 200-day moving average of $10.98. Oric Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.08. On average, analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ORIC. Guggenheim assumed coverage on Oric Pharmaceuticals in a report on Thursday, September 4th. They issued a “buy” rating and a $18.00 price target on the stock. HC Wainwright upped their target price on Oric Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Friday, November 14th. Wedbush reiterated an “outperform” rating and issued a $20.00 target price on shares of Oric Pharmaceuticals in a report on Monday, December 8th. Citigroup lifted their price target on shares of Oric Pharmaceuticals from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Evercore ISI started coverage on shares of Oric Pharmaceuticals in a report on Thursday, November 20th. They set an “outperform” rating and a $25.00 price objective on the stock. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Institutional Investors Weigh In On Oric Pharmaceuticals

Several institutional investors have recently bought and sold shares of ORIC. Vivo Capital LLC boosted its holdings in Oric Pharmaceuticals by 50.3% during the second quarter. Vivo Capital LLC now owns 3,126,604 shares of the company’s stock worth $31,735,000 after purchasing an additional 1,046,154 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Oric Pharmaceuticals by 3,646.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock valued at $13,555,000 after buying an additional 1,299,799 shares during the last quarter. Rafferty Asset Management LLC lifted its position in shares of Oric Pharmaceuticals by 50.7% during the 1st quarter. Rafferty Asset Management LLC now owns 77,424 shares of the company’s stock worth $432,000 after buying an additional 26,032 shares in the last quarter. Alkeon Capital Management LLC boosted its stake in shares of Oric Pharmaceuticals by 12.5% in the 2nd quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock worth $45,717,000 after buying an additional 500,000 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of Oric Pharmaceuticals in the 1st quarter worth approximately $935,000. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.